FDA Establishes Two Centers for Regulatory Science - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

FDA Establishes Two Centers for Regulatory Science


ePT--the Electronic Newsletter of Pharmaceutical Technology

On Oct. 26, 2011, FDA dedicated $2 million to support two regional Centers of Excellence in Regulatory Science and Innovation (CERSI). The centers, which will be located at the University of Maryland and at Georgetown University, will focus on the scientific knowledge and training needed to modernize and improve the ways the agency reviews and evaluates drugs and medical devices.

“These partnerships represent a critical, necessary, and creative investment—one that will benefit not just FDA and academia, but also American consumers and industry,” said FDA Chief Scientist Jesse L. Goodman in a press release. “The Centers of Excellence will create new scientific research, training, and staff-exchange opportunities for FDA and leading area institutions.”


CERSI researchers will cooperate with FDA scientists to stimulate innovation in medical-product development. The scientists also will aim to advance laboratory, population, behavioral, and manufacturing sciences. FDA chose to pilot the CERSI in the Washington, DC, area to allow for face-to-face collaboration and training with FDA staff.

FDA defines regulatory science as the science of developing new tools, standards, and approaches to assess the safety, efficacy, quality, and performance of all FDA-regulated products. For the past year, the agency has focused on improving regulatory science by launching various initiatives. Earlier this month, FDA launched an initiative titled “Driving Biomedical Innovation: Initiatives for Improving Products for Patients.” The initiative is an effort to increase the number of new-drug submissions by bringing stakeholders together to identify and overcome the challenges of product development and assessment.

In August 2011, FDA released its “Strategic Plan for Regulatory Science,” which describes the agency’s intent to improve the process for developing and evaluating new products from fields such as cell therapy, tissue engineering, genomics, personalized medicine, advanced computing, and information technology. It also emphasizes FDA’s intention to study and improve how it communicates health information to consumers.


See related Pharm Tech articles:

Prosperity through Biology (blog post)

FDA Outlines Strategy to Spur Biomedical Innovation (ePT)

Experts Ponder Ways to Fill Pharma Pipeline (Pharm Tech)

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here